Clinical trials: Patients With Advanced Solid Tumors
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Advanced Solid Tumors, Lymphoma
Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas
This phase 1 study of quarfloxin (CX-3543) is designed to test the safety, tolerability, and highest safe dose of this drug when administered intravenously weekly for three weeks of a four week cycle in patients with advanced…
- Trial name
- NCT00955292
- Testing
- Quarfloxin
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cylene Pharmaceuticals
Advanced Solid Tumor
Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
This study is a Phase I, open label, multi-center study of to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.
- Trial name
- NCT04689100
- Testing
- JMT101
- Where
- 9 sites in China
- Volunteers
- 259 people
- Sponsor
- Shanghai JMT-Bio Inc.
Advanced Solid Tumors
A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors
This trial is the first-in-human study of SYS6041, a multicenter, open-label, dose-escalation, dose-reassignment and cohort-expansion Phase I/IIa clinical study, which aims to evaluate the safety, tolerability, pharmacokinetic…
- Trial name
- NCT07744763
- Testing
- SYS6041
- Where
- China
- Volunteers
- 260 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Solid Tumors, Lymphoma, Non-Hodgkin
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
The study will evaluate the safety, tolerability, maximum administered dose, and dose limiting toxicity of SCH 727965 administered as an intravenous infusion on Days 1, 8 and 15 of each 28 day cycle in participants with solid…
- Conditions
- Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic. B-Cell
- Trial name
- NCT00871663
- Testing
- SCH 727965
- Volunteers
- 123 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Cancer, Solid Tumors
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
This study is a first-in-human, multicenter, open-label, nonrandomized, dose-escalation trial to be conducted in 2 sequential parts: Part A (Dose Escalation) in subjects with advanced malignancies Part B (Dose Confirmation) in…
- Trial name
- NCT02797795
- Testing
- NEV801
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Neovia Oncology Ltd.
Advanced Solid Tumor Malignancy
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
A Phase 1/2a, open-label, dose-escalation study with enrollment in Phase 1 to continue until determination of the Maximum Tolerated Dose (MTD) /Recommended Phase 2a Dose (RP2D), and then enrollment into Phase 2a expansion cohorts…
- Trial name
- NCT02380677
- Testing
- CRLX301
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- NewLink Genetics Corporation
Neoplasms, Breast Cancer
A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02129205
- Testing
- PF-06650808
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- Pfizer
Advanced Solid Tumor
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Based on overall response rate (ORR) as assessed by the Independent Review Committee (IRC) against the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria for Solid Tumor Efficacy, To evaluate the efficacy of…
- Trial name
- NCT06873854
- Testing
- LM-108, Toripalimab
- Where
- China
- Volunteers
- 84 people
- Sponsor
- LaNova Medicines Limited
Head and Neck Cancer, Cervical Cancer
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05955105
- Testing
- ILB-2109, Toripalimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Innolake Biopharm
Advanced Solid Tumor Malignancy
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors in monotherapy and in combination with anti programmed cell…
- Trial name
- CICILIA (NCT04260529)
- Testing
- CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
- Where
- 8 sites in France, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- Cytovation AS
Advanced Solid Neoplasms, Lymphoma Neoplasms
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
The purpose of this study is to assess the mass balance and to characterize the pharmacokinetics (PK) in plasma and urine, and of total radioactivity in plasma and whole blood following a single oral dose of [14C]-TAK-659…
- Trial name
- NCT03338881
- Testing
- [14C]-TAK-659, TAK-659
- Sponsor
- Calithera Biosciences, Inc
Recurrent Glioblastoma
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study.
- Trial name
- REGAL (NCT00777153)
- Testing
- Cediranib, Lomustine Chemotherapy
- Where
- 62 sites in United States, Australia and 8 more
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Solid Tumors
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with advanced solid tumors. The escalation part of the study will determine the maximum tolerated dose (MTD).
- Trial name
- NCT01313065
- Testing
- VX15/2503
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vaccinex Inc.
Neoplasms
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
This open label Phase I study involves treating subjects with advanced cancer with Copanlisib in combination with either gemcitabine or cisplatin plus gemcitabine.
- Trial name
- NCT01460537
- Testing
- Gemcitabine, BAY80-6946, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Bayer
Malignant Solid Tumors
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
This is a phase I, multicenter, open-label dose escalation and expansion study to evaluate genakumab alone and in combination with tislelizumab in adult patients with advanced solid malignancies.
- Trial name
- NCT05441046
- Testing
- Genakumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Advanced Solid Cancer, Metastatic Solid Tumor
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
- Conditions
- Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
- Trial name
- NCT06666270
- Testing
- SYN818
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Advanced Solid Tumors
Study With Atu027 in Patients With Advanced Solid Cancer
This is a phase I, prospective, open-label, single center, dose finding study with Atu027 (an siRNA formulation) given as single treatment followed by repeated treatment (repeated treatment phase: 8 treatments within 4 weeks) as…
- Trial name
- NCT00938574
- Testing
- Atu027
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Silence Therapeutics GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.